MedPath

AD-221

Generic Name
AD-221

Overview

No overview information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Research Report

Published: May 16, 2025

Comprehensive Report on AD-221 (Atorvastatin 5mg/Ezetimibe 10mg Fixed-Dose Combination)

1. Executive Summary

AD-221, a fixed-dose combination (FDC) of atorvastatin 5mg and ezetimibe 10mg, has emerged as a significant therapeutic option for primary hypercholesterolemia. Developed by Addpharma Co., Ltd. and marketed in South Korea as Atovamibe Tab. 10/5mg by Yuhan Corporation, this FDC leverages the complementary mechanisms of HMG-CoA reductase inhibition by atorvastatin and cholesterol absorption inhibition by ezetimibe. Clinical development, primarily through the Phase 3 trial NCT05131997, has demonstrated that AD-221 achieves superior low-density lipoprotein cholesterol (LDL-C) reduction (approximately 49%) compared to monotherapies with atorvastatin 5mg, ezetimibe 10mg, and even moderate-intensity atorvastatin 10mg. This enhanced efficacy allows a greater proportion of patients to achieve stringent lipid targets. Pharmacokinetic studies indicate that the FDC provides overall systemic exposure comparable to the co-administration of its individual components, despite some variations in peak concentrations for ezetimibe. The safety and tolerability profile of AD-221 is favorable, characterized by a low incidence of adverse events and, notably, no reported cases of myopathy or rhabdomyolysis in its pivotal Phase 3 study. Evidence also suggests a potentially better safety profile, including fewer liver enzyme elevations, compared to moderate-intensity atorvastatin monotherapy. Approved by the South Korean Ministry of Food and Drug Safety in May 2023, AD-221 (Atovamibe) is positioned as a valuable treatment for patients requiring substantial LDL-C lowering, particularly those who may benefit from a lower statin dose to enhance tolerability or for whom moderate-intensity statin monotherapy is insufficient.

2. Introduction

2.1. Context of Hypercholesterolemia and Lipid-Lowering Therapies

Continue reading the full research report

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.